...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Cardiopulmonary toxicity of different chemoradiotherapy combined regimens for Hodgkin's disease.
【24h】

Cardiopulmonary toxicity of different chemoradiotherapy combined regimens for Hodgkin's disease.

机译：不同化学放疗联合方案对霍奇金氏病的心肺毒性。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The majority of patients with Hodgkin's disease can be cured by combination of polychemotherapy and radiotherapy (RT) that can produce late toxic pulmonary and cardiac effects which often remain at a subclinical level. The aim of the present investigation was to compare the late pulmonary and cardiac toxicity of three chemotherapeutic regimens combined with RT and particularly doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD), vincristine, epirubicin, cyclophosphamide, etoposide and prednisone (VEBEP) and ABVD with mechloretamine, vincristine, procarbazine and prednisone (MOPP). PATIENTS AND METHODS: We investigated 147 patients suffering from Hodgkin's disease after a follow-up of at least 5 years from the completion of CT-RT. Seventy-eight patients were submitted to ABVD-RT, 36 to VEBEP-RT and 33 to MOPP-ABVD-RT. Patients underwent spirometry, 2D-doppler echocardiography at rest, cardiopulmonary exercise test on cycloergometer and determination of cardiac output by a non invasive method. RESULTS: Patients of the three different treatment groups showed tolerance to exercise, and oxygen consumption significantly lower than the predicted values but there were no statistically significant difference between the three groups. Nevertheless, patients treated with VEBEP and with MOPP-ABVD showed an ejection fraction at rest lower than those observed in the ABVD group and patients treated with VEBEP showed a cardiac output for oxygen uptake lower than those observed in the ABVD and MOPP-ABVD treatment groups. CONCLUSION: These data confirm that the combination of mediastinal RT with the more commonly used polychemotherapy regimens produce late toxic effects. The lower exercise capacity seems to be due to a combination of decreased cardiac performance and impairment of ventilation. The VEBEP regimens could be potentially more toxic for the heart, probably because of the higher cumulative dose of anthracyclines.
机译：霍奇金病的大多数患者可以通过多化学疗法和放射疗法（RT）的结合来治愈，后者可以产生晚期毒性的肺部和心脏效应，这些效应通常保持在亚临床水平。本研究的目的是比较三种化疗方案联合放疗的晚期肺和心脏毒性，尤其是阿霉素，博来霉素，长春碱和达卡巴嗪（ABVD），长春新碱，表柔比星，环磷酰胺，依托泊苷和泼尼松（VEBEP）和ABVD联合化疗甲草胺，长春新碱，丙卡巴肼和泼尼松（MOPP）。患者与方法：我们对完成CT-RT至少5年的随访的147名霍奇金病患者进行了调查。 78例患者接受ABVD-RT治疗，36例接受VEBEP-RT治疗，33例接受MOPP-ABVD-RT治疗。患者进行肺活量测定，休息时进行2D多普勒超声心动图检查，在心电描记器上进行心肺运动测试以及通过无创方法确定心输出量。结果：三个不同治疗组的患者显示出对运动的耐受性，耗氧量显着低于预期值，但三组之间无统计学差异。然而，接受VEBEP和MOPP-ABVD治疗的患者静息时的射血分数低于ABVD组所观察到的，而接受VEBEP治疗的患者表现出的摄氧量低于ABVD和MOPP-ABVD治疗组所观察到的。结论：这些数据证实纵隔放疗与更常用的多化学疗法联合使用可产生晚期毒性作用。较低的运动能力似乎是由于心脏功能下降和通气障碍共同造成的。 VEBEP方案对心脏可能具有更大的毒性，这可能是因为蒽环类药物的累积剂量更高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号